BBNX Beta Bionics, Inc.

BULLISH Impact: 8/10 8-K
Horizon days Filed Apr 21, 2026 Processed 1mo ago SEC 0001171843-26-002614
8-K Item 2.02: Earnings release
Latest settled — T+20d ⚠ clustered
BBNX ▼ -22.79% at T+20d
LONG call ✗ call lost -22.79% · α vs SPY -25.95% · entry $12.20 → $9.42
Next anchor: T+60d in 5w
Last close $13.87 (close Jun 8) · +13.69% from $12.20 entry
Entry anchored
Apr 21, 03:59 PM ET
via Databento tick
T+1d
-6.31%
call -6.31% · α -5.92%
$11.43
settled 7w ago
T+5d
-20.25%
call -20.25% · α -20.30%
$9.73
settled 6w ago
T+20d
-22.79%
call -22.79% · α -25.95%
$9.42
settled 22d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Beta Bionics reported strong Q1 2026 revenue growth of 57% year-over-year and raised full-year 2026 guidance for revenue, PBP channel penetration, and gross margin. Despite a sequential decline in new patient starts, the stock is likely to react positively due to the raised outlook and accelerating PBP channel growth.

Key Financial Metrics

Guidance
$131M-$136M
raised
Gross Margin
59.5%

Actionable Insight

The stock is likely to react positively to the raised guidance and strong PBP channel growth, despite the sequential decline in new patient starts. Monitor management's commentary on patient start trends during the earnings call for further clarity on demand sustainability.

Key Facts

  • Q1 2026 net sales of $27.6M, up 57% YoY
  • PBP channel sales up 181% YoY to $10.7M
  • Gross margin improved 864 bps YoY to 59.5%
  • Raised full-year 2026 revenue guidance to $131M–$136M (from $130M–$135M)
  • New patient starts declined sequentially by 10–20%

Financial Impact

Revenue beat consensus by $0.6M; raised full-year guidance signals accelerating commercial execution

revenuegross marginguidancePBP channel penetration

Risk Factors

  • Sequential decline in new patient starts may raise concerns about near-term demand
  • Net loss widened to $21.9M despite revenue growth, indicating ongoing profitability challenges

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-002614
Document: f8k_042126.htm0001171843-26-002614
Document: 0001171843-26-002614-index-headers.html0001171843-26-002614
Document: 0001171843-26-002614-index.html0001171843-26-002614
Document: 0001171843-26-002614.txt0001171843-26-002614
8-K Data (Synthetic)0001171843-26-002614
9 reports for BBNX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BBNX — sortable, filterable
Type Now
Jun 5, 2026
4d ago
Insider Cluster
NEUTRAL ★ 3/10
$13.78 awaiting T+1awaiting T+1$13.87 (+0.65%)
Jun 3, 2026
6d ago
Insider Cluster
NEUTRAL ★ 3/10
$13.89 $13.89· 0.00%▲ +2.60%$13.87 (−0.14%)
May 26, 2026
14d ago
Insider Cluster
NEUTRAL ★ 2/10
$11.63 $12.10▲ +4.04%▲ +3.50%$13.87 (+19.26%)
Apr 21, 2026
7w ago
8-K
BULLISH ★ 8/10
$12.20 $11.43▼ −6.31%▼ −5.92%$13.87 (+13.69%)
Apr 21, 2026
7w ago
Press Release
BULLISH ★ 8/10
$12.20 $11.43▼ −6.31%▼ −5.92%$13.87 (+13.69%)
Apr 10, 2026
8w ago
DEFA14A
NEUTRAL ★ 2/10
$10.63 $11.81▲ +11.10%▲ +9.89%$13.87 (+30.48%)
Mar 30, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$10.02 $10.01▼ −0.10%▼ −0.85%$13.87 (+38.42%)
Mar 2, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$12.52 $11.57▼ −7.59%▼ −6.67%$13.87 (+10.78%)
Mar 2, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$12.52 $11.57▼ −7.59%▼ −6.67%$13.87 (+10.78%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 5h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access